Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2014 1
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean imati (70 results)?
Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase.
Mattar M. Mattar M. Int J Hematol. 2010 Jan;91(1):104-6. doi: 10.1007/s12185-009-0431-1. Int J Hematol. 2010. PMID: 20054670
She rapidly achieved a complete hematologic response (CHR), at which point she switched therapy to a copy version of imatinib (Imatib). She received 400 mg/day of Imatib for 3 months, during which time her platelet count decreased from 250 x 10(9) to 105 x 10(9)/L a …
She rapidly achieved a complete hematologic response (CHR), at which point she switched therapy to a copy version of imatinib (Imatib …
Outcome of Frontline Treatment with "Generic" Imatinib In Adult Patients with Chronic Myeloid Leukemia in Algerian Population: A Multicenter Study.
Entasoltan B, Bekadja MA, Touhami H, Mehalhal N, Zouaoui Z, Mesli N, Talbi M, Bachiri A, Michallet M. Entasoltan B, et al. Mediterr J Hematol Infect Dis. 2017 Oct 25;9(1):e2017062. doi: 10.4084/MJHID.2017.062. eCollection 2017. Mediterr J Hematol Infect Dis. 2017. PMID: 29181139 Free PMC article.
The projected 5-year overall survival (OS) rate was 83%. Side effects of imatib (copy) in this study were similar to those reported previously for the entire imatinib mesylate treatment study and only 8% of patients were intolerant to imatib (copy) and treated with …
The projected 5-year overall survival (OS) rate was 83%. Side effects of imatib (copy) in this study were similar to those reported p …
Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report.
Goubran HA. Goubran HA. J Med Case Rep. 2009 Apr 29;3:7112. doi: 10.1186/1752-1947-3-7112. J Med Case Rep. 2009. PMID: 19830137 Free PMC article.
CASE PRESENTATION: This report describes the loss of response in a 36-year-old male patient with chronic-phase chronic myeloid leukemia who had previously been in full hematologic and cytogenetic remission and partial molecular remission for three years, under treatment with bran …
CASE PRESENTATION: This report describes the loss of response in a 36-year-old male patient with chronic-phase chronic myeloid leukemia who …